252 related articles for article (PubMed ID: 30816441)
21. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
[TBL] [Abstract][Full Text] [Related]
22. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
23. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
24. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
[TBL] [Abstract][Full Text] [Related]
25. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
Ren X; Liu H; Zhang M; Wang M; Ma S
Mol Med Rep; 2016 Sep; 14(3):2431-8. PubMed ID: 27484725
[TBL] [Abstract][Full Text] [Related]
26. [Effects of small interfering RNA specific to stably transfected HMGA1 gene on biological characters of ovarian carcinoma cells].
Liu YL; Zheng JH
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):51-5. PubMed ID: 20367927
[TBL] [Abstract][Full Text] [Related]
27. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
28. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
van Jaarsveld MT; van Kuijk PF; Boersma AW; Helleman J; van IJcken WF; Mathijssen RH; Pothof J; Berns EM; Verweij J; Wiemer EA
Mol Cancer; 2015 Nov; 14():196. PubMed ID: 26576679
[TBL] [Abstract][Full Text] [Related]
29. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells.
Cao YD; Huang PL; Sun XC; Ma J; Jin ZL; Cheng HY; Xu RZ; Li F; Qin SK; Deng YX; Ge XL
Chin Med J (Engl); 2011 Apr; 124(7):1061-8. PubMed ID: 21542969
[TBL] [Abstract][Full Text] [Related]
30. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
31. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2.
Liang L; Li X; Zhang X; Lv Z; He G; Zhao W; Ren X; Li Y; Bian X; Liao W; Liu W; Yang G; Ding Y
Gastroenterology; 2013 Mar; 144(3):624-635.e4. PubMed ID: 23201162
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
35. TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.
Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
[TBL] [Abstract][Full Text] [Related]
36. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs.
D'Angelo D; Mussnich P; Rosa R; Bianco R; Tortora G; Fusco A
BMC Cancer; 2014 Nov; 14():851. PubMed ID: 25409711
[TBL] [Abstract][Full Text] [Related]
37. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p.
Wang C; Qi S; Xie C; Li C; Wang P; Liu D
J Gynecol Oncol; 2018 Nov; 29(6):e99. PubMed ID: 30207107
[TBL] [Abstract][Full Text] [Related]
39. Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
Miao F; Zhang X; Cao Y; Wang Y; Zhang X
BMC Cancer; 2017 Dec; 17(1):838. PubMed ID: 29228922
[TBL] [Abstract][Full Text] [Related]
40. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]